Lupin gets non-exclusive license from TB Alliance to manufacture anti-TB drug pretomanid

06 Sep 2021 Evaluate

Lupin has been granted non-exclusive license from TB Alliance to manufacture the anti-TB drug pretomanid as part of the three-drug ‘BPaL’ regimen. Lupin intends to commercialize the antituberculosis (TB) medicine in approximately 140 countries and territories, including many of the highest TB burden countries around the world. 

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.

Lupin Share Price

2151.05 19.25 (0.90%)
30-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1595.00
Dr. Reddys Lab 1218.40
Cipla 1323.95
Zydus Lifesciences 885.20
Lupin 2151.05
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×